Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor

In brief

This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.

Key facts

Study ID
NCT04901806
Run by
Pyramid Biosciences
People needed
29
Starts
2021-07-20
Expected to finish
2023-07-26
Last updated by the study team
2024-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.